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been introduced recently as an alternative for oral anticoagulation
(OAC) in patients with nonvalvular atrial ﬁbrillation (AF). Because
of potential overlap of ablation target areas and the previously
implanted LAA closure device, as well as potential complications
such as mechanical damage to the device, left atrial (LA) ablation
remains a subject of debate in these patients.
OBJECTIVE We report on the feasibility and clinical efﬁcacy of LA
ablation after implantation of LAA closure devices.
METHODS Eight patients (6 men; age 69  8 years) with
symptomatic paroxysmal AF (n ¼ 5) or persistent AF (mean
CHA2DS2-VASc score 3.6  0.7, mean HAS-BLED score 3.6  1.5)
and previously implanted WATCHMAN (7 patients) or AMPLATZER
Cardiac Plug (1 patient) LAA closure devices received
radiofrequency-based LA ablation (4 via circumferential pulmonary
vein isolation [CPVI], 4 via CPVI and additional LA linear lesions or
complex fractionated atrial electrograms) after a mean of 201 days
(range 41–756 days) after LAA closure.
RESULTS Successful LA ablation was achieved without device
interference or periprocedural complications. After a mean of
503 days (range 113–1006 days), transesophageal echocardiog-
raphy (TEE) was performed in all patients to assess for device-
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found despite therapeutic OAC with dabigatran. Five patients
(63%) remained in stable sinus rhythm, and no bleeding events
or stroke occurred during a follow-up of 554 days (range 218–
1006 days).
CONCLUSION LA ablation after LAA closure appears to be feasible.
Device-related thrombus formation in 1 patient suggests the need
for further TEE examinations after LA ablation after LAA closure
device implantation.
KEYWORDS Atrial ﬁbrillation; Catheter ablation; Left atrial
appendage closure; Stroke prevention
ABBREVIATIONS ACP ¼ AMPLATZER Cardiac Plug; AF ¼ atrial
ﬁbrillation; ASA ¼ acetylsalicylic acid; CFAE ¼ complex
fractionated atrial electrogram; CPVI ¼ circumferential
pulmonary vein isolation; LA ¼ left atrium/atrial; LAA ¼ left
atrial appendage; LATA ¼ left atrial tachyarrhythmia; NOAC ¼
novel oral anticoagulant agent; OAC¼ oral anticoagulation; PAF¼
paroxysmal atrial ﬁbrillation; PV ¼ pulmonary vein; TEE ¼
transesophageal echocardiography; TIA ¼ transient ischemic
attack; WATCHMAN ¼ WATCHMAN LAA closure device
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Atrial ﬁbrillation (AF) is currently the most common
arrhythmia in the developed world, with an incidence of
1.5%–2% in the general population.1 The risk of stroke is
increased in patients with AF and is estimated to be as high
as 5% per year.2 The left atrial appendage (LAA) is the
primary source for thrombus formation and subsequent
cardiac embolism in patients with nonvalvular AF.2
Recently, percutaneous LAA closure devices were intro-
duced for stroke prevention in patients with nonvalvular AF,
and their safety and feasibility have been demonstrated in
large trials.3 This has led to their inclusion in the latest
European Society of Cardiology guidelines for the treatmenthttp://dx.doi.org/10.1016/j.hrthm.2015.03.011
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lation (OAC) and a high HAS-BLED score (a score that
assigns 1 point for each of the following: hypertension,
abnormal renal or liver function, previous stroke, bleeding
history or predisposition, labile international normalized
ratios, elderly, and concomitant drug or excessive alcohol
use).1 Circumferential pulmonary vein isolation (CPVI) is
now an established treatment strategy for patients with
symptomatic, drug-refractory AF.4,5 The feasibility of CPVI
and other left atrial (LA) ablation strategies in patients with
LAA closure devices remains unclear.6 We report on the
feasibility and clinical efﬁcacy of CPVI and additional LA
ablation techniques for the treatment of LA tachyarrhythmias
(LATAs) in patients with previously implanted LAA closure
devices.
Methods
This was a retrospective, single-center study. All patient
information was anonymized. Eight consecutive patients
(age 69  8 years) with paroxysmal AF (PAF, n ¼ 5) or
persistent AF (n ¼ 3/8) after successful percutaneous LAA
closure with subsequent LA ablation for the treatment of
LATA were included. Before LA ablation, all patients
underwent transesophageal echocardiography (TEE) to
exclude possible intracardiac thrombus formation and to
evaluate the previously implanted LAA closure device for
device leakage or dislocation. Individual HAS-BLED score
and CHA2DS2-VASc score (congestive heart failure [1
point], hypertension [1 point], age Z75 years [2 points],
diabetes mellitus [1 point], stroke/transient ischemic attack
[TIA]/thromboembolism [2 points], vascular disease [1
point], age 65 to 74 years [1 point], female [1 point]) were
calculated for each patient.
LAA closure procedure
In patients with documented nonvalvular AF, percutaneous
LAA closure was performed per the patient’s preference in
those deemed to have high risk for bleeding (n ¼ 4; mean
HAS-BLED score 3.7  0.6) and in those with severe
bleeding who were undergoing OAC treatment (n¼ 4). LAA
closure was achieved with either the WATCHMAN LAA
closure device (Boston Scientiﬁc, Natick, MA; sizes 21 mm
[n¼ 1], 24 mm [n¼ 2], 27 mm [n¼ 3], and 33 mm [n¼ 1])
or the AMPLATZER Cardiac Plug (ACP) LAA closure
device (St. Jude Medical, St. Paul, MN; size 22 mm [n ¼
1]). Before each procedure, all patients underwent TEE to
exclude LA thrombus and to assess LAA anatomy. The
LAA closure procedure was performed according to the
latest guidelines.2 In brief, all procedures were guided by
TEE, and after a single transseptal puncture by use of the
modiﬁed Brockenbrough technique and an SL1 transseptal
sheath (St. Jude Medical), boluses of unfractionated
heparin were administered intravenously throughout the
procedure to achieve an activated clotting time 4250
seconds. The SL1 transseptal sheath was then exchanged
for the appropriate LAA closure device sheath. A 7F pigtailcatheter was advanced into the LAA via the LAA closure
device sheath, and LAA angiograms were performed (right
anterior oblique 301 and caudal 201; left anterior oblique
401) to visualize the LAA morphology and assess LAA
diameters. To avoid device-related complications such as
device embolization or leakage, as well as to allow for
stable positioning, a device size 10%–20% larger than the
largest diameter of the LAA landing zone was chosen, in
accordance with current recommendations.2 Before the
LAA closure device was released, proper device position-
ing was veriﬁed by angiography and TEE, followed by the
“tug test.”2 The device was repositioned if any leakage was
seen, and the ﬁnal position was conﬁrmed by angiography
and TEE.
All patients were discharged the next day after a
transthoracic echocardiography to rule out complications
such as pericardial effusion. After implantation of the LAA
closure device, all patients were treated with OAC or dual-
antiplatelet therapy if OAC was contraindicated. After 6 to
12 weeks, a follow-up TEE was performed to assess for
device-related thrombus formation, device dislocation, or
residual leakage. If no thrombus formation or residual ﬂow
was found, OAC was stopped, and the patient was treated
with acetylsalicylic acid (ASA, 100 mg/d) or clopidogrel
(75 mg/d) if the patient was allergic or intolerant to
ASA.
Electrophysiological study and LA mapping
The methods of our ablation strategy have been described in
detail elsewhere.5,7 In brief, all procedures were performed
under deep sedation with midazolam, fentanyl, and a
continuous propofol infusion. A diagnostic catheter was
positioned inside the coronary sinus. After double transseptal
punctures were performed by a modiﬁed Brockenbrough
technique, 2 SL1 transseptal sheaths (St. Jude Medical) were
advanced into the LA. Activated clotting time was assessed
every 30 minutes, and intravenous heparin boluses were
administered, targeting an activated clotting time 4250
seconds. Both transseptal sheaths were continuously ﬂushed
with heparinized saline to prevent thrombus formation. One
SL1 sheath was then used for the multielectrode spiral
mapping catheter (Lasso, Biosense Webster Inc, Diamond
Bar, CA, or AFocus, St. Jude Medical). Three-dimensional
electroanatomic LA reconstruction with a 3-dimensional
mapping system (CARTO, Biosense Webster) was per-
formed with a conventional 3.5-mm irrigated-tip ablation
catheter (THERMOCOOL NAVISTAR, Biosense Webster).
Selective angiography of each pulmonary vein (PV) via right
anterior oblique 301 and left anterior oblique 401 ﬂuoro-
scopic views was then performed.
Ablation protocol
LA ablation with irrigated radiofrequency was performed in
all patients according to our institutional standard, as
described previously.5 A maximum temperature cutoff of
431C and maximum power cutoffs of 30 W at the posterior
Table 1 Patient baseline characteristics
Patients (n) 8
Age (y) 69  8
Female, n (%) 2 (25)
Left atrial size, mean (mm) 48  8
Paroxysmal AF, n (%) 5 (63)
Persistent AF, n (%) 3 (38)
Mean HAS-BLED score 3.6  1.5
Mean CHA2DS2-VASc score 3.6  0.7
Mean procedure time (min) 178.1  41.7
Mean ﬂuoroscopy time (min) 19.3  9.1
Values are mean  SD or n (%) as appropriate.
AF ¼ atrial ﬁbrillation; CHA2DS2-VASc, score that assigns points for
congestive heart failure (1 point), hypertension (1 point), ageZ75 years (2
points), diabetes mellitus (1 point), stroke/transient ischemic attack/
thromboembolism (2 points), vascular disease (1 point), age 65 to 74 years
(1 point), and female sex (1 point); HAS-BLED, score that assigns 1 point
each for hypertension, abnormal renal or liver function, previous stroke,
bleeding history or predisposition, labile international normalized ratios,
elderly, and concomitant drug or excessive alcohol use.
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catheter infusion rate of 17 to 25 mL/min. During CPVI, a
multielectrode spiral mapping catheter was positioned inside
the ipsilateral PVs. The endpoint for CPVI was the absence
of any PV spike recorded on a spiral catheter placed within
the ipsilateral PVs at least 30 minutes after PV isolation
during sinus rhythm.4,5,8
For macroreentrant LATA, ablation of linear lesions was
performed. The electrophysiologic endpoint of bidirectional
block of the linear lesion was conﬁrmed during sinus rhythm
by use of pacing maneuvers as described previously.9–11
Ablation of complex fractionated atrial electrograms
(CFAEs) was only performed if (1) direct current cardio-
version failed after CPVI or (2) patients demonstrated no PV
reconduction at repeat ablation.5 The technique of CFAE
ablation was performed as described previously.7 During all
procedures within the LA, close visual monitoring of
catheter impedance was performed to avoid device-related
complications.In-hospital evaluation and follow-up
After procedures, all patients underwent transthoracic echo-
cardiography to exclude pericardial effusion. The use of
periprocedural and postprocedural OAC was discussed and
performed in agreement with both patients and referring
physician on an individual base. Generally, it was recom-
mended from our institution as follows: In patients taking
warfarin before ablation, bridging with low-molecular-
weight heparin was given until an international normalized
ratio 42 was reached. Novel oral anticoagulant agents
(NOACs) were initiated at half the regular dose, 6 hours
after ablation. Full-dose NOACs were then started the day
after ablation and continued for 3 months with conversion
to ASA or clopidogrel thereafter. Antiarrhythmic drugs
taken before the ablation procedure were continued for a
minimum of 3 months after ablation, and all patients
received proton pump inhibitors for 6 weeks. During
follow-up, TEE and clinical assessments were performed
to determine whether LA ablation led to LAA closure
complications such as device dislocation, LAA leakage, or
device-related thrombus formation or to clinical compli-
cations such as TIA, stroke, peripheral embolism, or
bleeding events. Recurrence of LATA was assessed by
24-hour Holter-monitoring. Arrhythmia recurrence was
deﬁned as documented LATA that lasted at least 30
seconds after a 3-month blanking period.Statistical analysis
Statistical analysis was performed with GraphPad Prism
version 5 (GraphPad Software, Inc, San Diego, CA). All
results are reported as values and percentages, mean 
standard deviation, or median and minimal and maximal
values as appropriate.
All authors had full access to the data and have read and
agreed to the manuscript as written.Results
Patient baseline characteristics
Patient baseline characteristics are reported in Table 1. A
total of 8 patients were evaluated. The indication for LA
ablation was the treatment of symptomatic, drug-refractory
AF. The mean CHA2DS2-VASc score was 3.6  0.7 (range
1–6) and the mean HAS-BLED score was 3.6  1.5
(range 3–5).
Acute success rate of LAA closure
In all patients, successful LAA occlusion was achieved
without evidence of residual ﬂow in the ﬁnal TEE evalua-
tion. No peri-interventional complications occurred, and all
patients were discharged on day 1 after the procedure.
Follow-up after LAA closure
After LAA closure, 6 patients were treated with OAC,
whereas 2 were treated with dual-antiplatelet therapy
because of a contraindication to OAC. After a median of
74 (41–122) days, a TEE was performed in all patients.
When no device-related thrombus formation, device dislo-
cation, or leakage was found, OAC/dual-antiplatelet therapy
was stopped and changed to ASA 100 mg/d (n ¼ 7) or
clopidogrel 75 mg/d (in 1 patient allergic to ASA).
LA ablation procedure after LAA closure
Ablation procedural details are presented in Table 2. LA
ablation was performed 201 days (range 41–756 days) after
the LAA closure procedure. No device-related thrombus
formation, device dislocation, or leakage was found on TEE
1 day before or on the day of the LA ablation procedure.
Ablation performed at the index procedure included CPVI in
6 patients, reisolation of the left PVs in 2 patients (1 closure
of an anteroinferior gap, and ablation of ostial potentials
along the ridge between the left PVs and the LAA in 1
patient), ablation of an anterior line in 3 patients, mitral
isthmus line ablation in 3 patients, and ablation of CFAEs
Table 2 Details of LAA closure, LA ablation, and follow-up examinations
Patient
Device
(size)
Indication
for LAA
closure
Time from
LAA closure
to LA
ablation (d)
PAF/
persistent
AF Previous LA ablation Index procedure Postablation OAC
Follow-up: Device-
related
complications
assessed by TEE (d)
Follow-up:
AT/AF
recurrence
(d)
Follow-up:
Clinical
complications
1 ACP (22
mm)
Risk for
bleeding
(HAS-BLED
score ¼ 6)
234 PAF … CPVI Warfarin (INR 2–3) 0 (759) 0 (622) 0
2 WATCHMAN
(33 mm)
Previous
severe
bleeding
under OAC
182 PAF CPVI CPVI Rivaroxaban (20 mg/d) 0 (778) 1 (778) 0
3 WATCHMAN
(21 mm)
Previous
severe
bleeding
under OAC
133 PAF … CPVI Rivaroxaban (20 mg/d) 0 (464) 0 (466) 0
4 WATCHMAN
(24 mm)
Previous
severe
bleeding
under OAC
105 Persistent
AF
CPVI Ablation of anterior þ
mitral isthmus line þ
ostial potentials
Apixaban (5 mg twice daily) 0 (504) 0 (400) 0
5 WATCHMAN
(24 mm)
Risk for
bleeding
(HAS-BLED
score ¼ 4)
41 PAF … CPVI Apixaban (5 mg twice daily) 0 (187) 0 (266) 0
6 WATCHMAN
(27 mm)
Previous
severe
bleeding
under OAC
92 PAF … CPVI, ablation of an
anterior line
Rivaroxaban (20 mg/d) 0 (218) 1 (218) 0
7 WATCHMAN
(27 mm)
Risk for
bleeding
(HAS-BLED
score ¼ 3)
756 Persistent
AF
CPVI þ LAA isolation
via ablation of
anterior þ mitral
isthmus line
Reisolation of LAA via
mitral isthmus line
Dabigatran (150 mg twice
daily)
0 (1006) 0 (1006) 0
8 WATCHMAN
(27 mm)
Risk for
bleeding
(HAS-BLED
score ¼ 3)
63 Persistent
AF
… CPVI, ablation of CFAEs
in CS and LA þ
anterior þ mitral
isthmus line
Dabigatran (150 mg twice
daily); rivaroxaban (20
mg/d); apixaban (5 mg
twice daily)
Thrombus (113) 1 (673) 0
ACP¼ AMPLATZER Cardiac Plug left atrial appendage closure device; AF¼ atrial ﬁbrillation; AT¼ atrial tachycardia; CFAE¼ complex fractionated atrial electrogram; CPVI¼ pulmonary vein isolation; CS¼ coronary
sinus; HAS-BLED, score that assigns 1 point each for hypertension, abnormal renal or liver function, previous stroke, bleeding history or predisposition, labile international normalized ratios, elderly, and concomitant
drug or excessive alcohol use; INR ¼ international normalized ratio; LA ¼ left atrium; LAA ¼ left atrial appendage; OAC ¼ oral anticoagulation; PAF ¼ paroxysmal atrial ﬁbrillation; TEE ¼ transesophageal
echocardiography; WATCHMAN ¼ WATCHMAN left atrial appendage closure device.
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Figure 1 WATCHMAN left atrial (LA) appendage closure device before and after LA ablation. Transesophageal echocardiography ﬁndings of the LA before
(A and C) and after LA ablation (B and D) in 2 representative patients after LA appendage closure with the WATCHMAN device. In patient 6, no dislocation,
leakage, or thrombus formation was detected before (A) or after (B) LA ablation. In patient 8 (C), no dislocation, leakage, or thrombus formation was found
before LA ablation; however, at follow-up, 113 days after LA ablation, a sessile device-related thrombus (10  12 mm, attached to the superior-anterior part of
the device; red arrow in D) was detected while the patient was undergoing therapy with dabigatran. AV ¼ aortic valve; LA ¼ left atrium; WATCHMAN ¼
WATCHMAN LAA closure device.
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all procedures, all PVs were successfully reisolated/isolated,
and bidirectional block was achieved at all lines that were
applied. No periprocedural complications were documented,
and no automatic generator shutoff occurred because of
erroneous impedance measurements in the area of the
implanted LAA closure device. Sinus rhythm was achieved
in all patients.Postprocedural anticoagulation
After LA ablation, OAC was achieved (1 with warfarin
[international normalized ratio 2–3]; 3 with rivaroxaban 20
mg/d; 2 with apixaban 5 mg twice daily; and 2 with
dabigatran 150 mg twice daily) and was continued for at
least 3 months after LA ablation. After 3 months, ASA
(100 mg/d) was prescribed in 4 patients and clopidogrel
(75 mg/d) in 1 patient, whereas in 2 patients, apixaban was
continued at half of the regular dose (2.5 mg twice daily).
Because of a device-related thrombus formation, 1 patient
treated initially with dabigatran was switched to rivarox-
aban (20 mg/d).TEE results after LA ablation and incidence of
device-related complications
All patients received TEE evaluation after a mean of 503
days (113–1006 days) after the LA ablation procedure.
Representative TEE images are shown in Figure 1
(WATCHMAN) and Figure 2 (ACP). No device dislocation
or leakage was found. In 1 patient (patient 8), a device-
related thrombus (10  12 mm) was detected 113 days after
LA ablation while the patient was being treated with
dabigatran (150 mg twice daily). OAC was arbitrarily
changed to rivaroxaban (20 mg/d), and another TEE was
performed at 4-month follow-up. At that time, the thrombus
remained unchanged, and OAC was changed to apixaban (5
mg twice daily). TEE was then repeated at 5, 6, 8, 10, 12, and
15 months after LA ablation. Under treatment with apixaban,
a continuous reduction in the thrombus size was observed,
and the thrombus resolved 616 days (420 months) after the
LA ablation. This patient remains under surveillance and is
maintained on therapeutic apixaban (5 mg twice daily). To
date, no thrombus-related events such as TIA, stroke, or
peripheral embolism have occurred, and no bleeding events
have been reported (follow-up of 673 days).
Figure 2 AMPLATZER left atrial (LA) appendage closure device before and after LA ablation. Transesophageal echocardiography ﬁndings of the LA before
(A) and after (B) LA ablation in patient 1 after LA appendage closure with the AMPLATZER device. No dislocation, leakage, or thrombus formation was
detected before or after LA ablation. APC ¼ AMPLATZER Cardiac Plug LAA closure device; MV ¼ mitral valve.
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Follow-up data are provided in Table 2. After a mean follow-
up of 554 days (range 218–1006 days), 5 patients (63%)
were in stable sinus rhythm without documentation of any
LATA. In the other 3 patients (38%), LATA recurrence was
detected. No bleeding events or stroke, TIA, or peripheral
embolism occurred in this study population.Discussion
This retrospective analysis provides serial data regarding the
feasibility and clinical efﬁcacy of LA ablation procedures in
patients with nonvalvular AF and percutaneous LAA closure
devices. The main ﬁndings were as follows: (1) LA ablation
after percutaneous LAA closure is feasible, resulting in
successful CPVI and bidirectional blockade of additional
LA ablation lines. (2) Device-related thrombus formation
may occur after ablation in these patients.
Because of an increasing number of patients with non-
valvular AF and an increasing rate of LAA closure device
implantations, LA ablation for the treatment of symptomatic
drug-refractory LATA remains a subject of debate in patients
after LAA closure and will play an increasing role in the
future.6,12 There is a certain risk that ablation at the
previously implanted LAA closure device site or in its very
close proximity will be required. In addition, radiofrequency
application near the LAA closure device or catheter-device
contact during ablation could lead to mechanically induced
damage of the endothelialization of the device or even device
dislocation. This may increase the risk of thrombus for-
mation at the site of endothelialization damage or lead to
leakage. A further consideration concerning endothelial
tissue damage during radiofrequency-based LA ablation in
patients with LAA closure devices refers to the metal
structure of the device itself. Recently, Deneke et al13 found
a high incidence of esophageal alterations in patients with
luminal esophageal temperature monitoring via metal esoph-
ageal probes during LA ablation. A thermal effect of the
metal luminal esophageal temperature probe caused byradiofrequency-induced electrical current was suggested to
be responsible for the observed effect.13,14 Similar mecha-
nisms could be responsible for endothelial damage and
subsequent device-related complications, including throm-
bus formation, even without catheter-device contact.
To date, to the best of our knowledge, there has been only
1 case report of LA ablation in a patient with a previously
implanted ACP device.6 Recently, Swaans and colleagues15
reported 4 cases of LA ablation in patients with previously
implanted WATCHMAN devices; however, no clinical
follow-up data that include TEE or rate of LATA recurrence
have been reported.Device-related complications of LA ablation
after LAA closure
In the present cohort, no periprocedural complications
occurred. Nevertheless, a device-related thrombus was
detected in 1 patient while the patient was undergoing
OAC with dabigatran 113 days after LA ablation. This
thrombus persisted for420 months despite continuation of
therapeutic OAC with alternative NOACs. In the
PROTECT-AF trial (WATCHMAN Left Atrial Appendage
System for Embolic Protection in Patients With Atrial
Fibrillation), device-associated thrombi were observed in
4.2% of patients after LAA closure with the WATCHMAN
device who were undergoing OAC with warfarin.16 We
cannot exclude that the device-related thrombus in the 1
patient in the present study occurred coincidentally after
ablation; however, our patient had no device-related throm-
bus on TEE 62 days after LAA closure, which was 1 day
before LA ablation, but had a thrombus on TEE after LA
ablation. Consequently, although a causal relation between
the procedure and the thrombus formation on the LAA
closure device remains unproven, it is very likely. Ablation
was performed only 63 days after LAA closure. Therefore, it
may be possible that the device was only covered by a thin,
fragile layer of endothelial tissue, which could be potentially
injured and promote thrombus formation. Therefore, we
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termination of OAC to assess for device-related complica-
tions after LA ablation. In the case of postprocedural device-
related thrombus formation, it seems to be advisable to
extend OAC, despite the increased risk of bleeding events, to
prevent ischemic complications. No data are available for
this speciﬁc patient population. Therefore, the indication for
OAC must be discussed and performed individually.
We hypothesize that radiofrequency-induced electrical
current to the metal of the device might cause endothelial
tissue damage and subsequent device-related thrombus
formation, similar to what has been described for the luminal
esophageal temperature probe.13,14 Radiofrequency delivery
in close proximity to LAA closure devices could result in
erroneous impedance measurements and therefore automatic
generator shutoff. Although this has been reported previ-
ously in an ACP LAA closure device,6 no impedance
interference occurred in our cohort, particularly in the patient
who developed device thrombus. Nevertheless, we recom-
mend close impedance monitoring during LA ablation in
patients with implanted LAA closure devices to avoid
device-related complications.Feasibility of LA ablation after LAA closure
CPVI has proven to be an effective treatment strategy for
patients with PAF even after long-term follow-up.4 Never-
theless, the success rates in patients with persistent AF and
long-standing persistent AF remain mediocre, and multiple
ablation procedures with diverse complex ablation techni-
ques are often required to achieve and maintain sinus
rhythm.5,7 In our study, CPVI and more complex LA
ablation techniques, including linear lines, LAA isolation,
and CFAE ablation, were performed.
Because of the limited number of patients in this hetero-
geneous study population, comparison with a control group
is of limited value. Therefore, outcome data after LAA
occlusion must be evaluated in the future in larger patient
populations with adequate control groups. However, the
ﬁndings are mainly in line with previously published success
rates from our center.4,5,17 Therefore, with 5 of 8 patients
remaining in stable sinus rhythm within the observed follow-
up period, we suggest that LA ablation in patients with
previously implanted LAA closure devices is feasible and
effective.
The latest long-term clinical follow-up data from the
randomized controlled PROTECT-AF trial and the recently
published PREVAIL trial (WATCHMAN LAA Closure
Device in Patients With Atrial Fibrillation Versus Long
Term Warfarin Therapy) demonstrated the efﬁcacy and
safety of the WATCHMAN device compared with
OAC.3,18 In comparison, only registry data are available
for the ACP LAA closure device.19 Nevertheless, these
registries have shown promising results, and the ACP device
is used extensively in clinical practice.20–22 The ACP device
contains a proximal disc that extends outside the ostium of
the LAA toward the LA ridge. This proximal disc completelyoccludes the LAA oriﬁce and may lead to a superior
complete LAA occlusion rate compared with the WATCH-
MAN device.2 However, because of the overlap of this disc
and the LA ridge, successful LA ablation in these patients
may be technically more difﬁcult than for patients implanted
with the WATCHMAN device, which has no overhanging
parts.6 Nevertheless, in the patient with the previously
implanted ACP device, successful CPVI was performed
without any device-related complications, and clinical suc-
cess without LATA recurrence after a follow-up of 420
months has been documented.
Unpublished data presented by Dr Vivek Reddy at the
Transcatheter Cardiovascular Therapeutics 2014 meeting
provided evidence for late ischemic strokes that occurred
in the WATCHMAN arm of the PROTECT-AF trial, which
called the safety and efﬁcacy of this system into question.23
To improve patient outcome, several new LAA closure
devices are being developed at present, some of which
require no thrombogenic endocardial device to be left
behind. These novel methods may make subsequent LA
ablation less difﬁcult.24 Nevertheless, the feasibility and
safety of these new devices must be proven in upcoming
trials.25Study limitations
The periprocedural OAC regimen was not standardized.
Patients given warfarin and those given different NOACs
were included in this analysis. There is no optimal OAC
protocol for these patients, and therefore, periprocedural and
postprocedural OAC were discussed and performed individ-
ually as agreed to by patients and their referring physicians.
The patient cohort was relatively small. However, to the best
of our knowledge, this is the ﬁrst case series to describe the
feasibility and clinical efﬁcacy of catheter ablation in patients
with LAA closure devices that included TEE-based follow-
up examinations. Follow-up assessments for LATA recur-
rence were performed using only 24-hour Holter monitoring,
and recurrence may be underestimated. TEE assessment was
performed at different time points after LA ablation, and
therefore, transient thrombus formation in the early phase
after ablation cannot be excluded; thus, the optimal time
point for LA ablation after LAA closure and TEE follow-up
after LA ablation in patients with previous LAA closure
device implantation is unknown. Larger multicenter studies
are required to conﬁrm our results.Conclusion
This report demonstrates the feasibility and clinical efﬁcacy
of LA ablation after percutaneous LAA closure device
implantation, without intraprocedural or periprocedural
device interference, dislocation, or leakage. Thrombus for-
mation occurred in 1 patient after LA ablation. Thus, we
recommend TEE evaluation after LA ablation in patients
with previously implanted LAA closure devices to assess for
device-associated complications.
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1790–1798.CLINICAL PERSPECTIVES
Because of potential overlap of ablation target areas and a previously implanted LAA closure device, LA ablation for the
treatment of LATA remains a subject of debate. We present the ﬁrst serial data regarding feasibility and clinical efﬁcacy of
LA ablation in patients with previously implanted LAA closure devices. A TEE was performed in all patients to assess for
device-related complications. No device dislocation or leakage was observed after a mean of 503 days. In 1 patient, a
device-related thrombus was found despite therapeutic OAC. Five of 8 patients (63%) remained in stable sinus rhythm, and
no bleeding events or stroke occurred during a follow-up of 554 days (range 218–1006 days). LA ablation after LAA
closure appears to be feasible, resulting in successful CPVI and bidirectional blockade of additional LA ablation lines.
Device-related thrombus formation may occur after ablation in these patients, which suggests the need for further
examinations after LA ablation to improve patient safety. We recommend TEE evaluation after LA ablation in patients with
previously implanted LAA closure devices to assess for device-associated complications. Larger studies are required to
conﬁrm our results.
